CD274 and Merkel cell skin cancer: Based on an ORR of 31.8% in patients with Merkel cell carcinoma in phase 2 study, avelumab became the first-approved anti-PD-L1 antibody for this rare and aggressive skin cancer (Kaufman et al., 2016).